Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study

…, B Frederick, B Van Hartingsveldt… - British journal of …, 2011 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Interleukin (IL)‐6 is a cytokine
known for pleiotropic and pro‐inflammatory functions. IL‐6 is involved in various disease …

Phase I, randomized, double‐blind, placebo‐controlled, multiple intravenous, dose‐ascending study of sirukumab in cutaneous or systemic lupus erythematosus

…, A Reich, DE de Vries, B van Hartingsveldt… - Arthritis & …, 2013 - Wiley Online Library
Objective We undertook a 2‐part, phase I, double‐blind, placebo‐controlled study to evaluate
the safety and pharmacokinetics of multiple intravenous infusions of sirukumab, a human …

A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular …

…, Y Zhu, D Sisco, B Van Hartingsveldt… - The Journal of …, 2006 - jrheum.org
OBJECTIVE: To assess safety, clinical response, and pharmacokinetics of subcutaneous (SC)
and intramuscular (IM) doses of an experimental formulation of infliximab [including …

Safety, tolerability and pharmacokinetics of a human anti‐interleukin‐13 monoclonal antibody (CNTO 5825) in an ascending single‐dose first‐in‐human study

B van Hartingsveldt, IP Nnane… - British Journal of …, 2013 - Wiley Online Library
Aims To assess the safety, tolerability, pharmacokinetics ( PK ), pharmacodynamics (PD) and
immunogenicity of CNTO 5825 following single‐dose intravenous (iv) and subcutaneous (…

LP-195 Design of a Phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus

F Liu-walsh, B van Hartingsveldt, Q Zuraw, R Hoffman… - 2023 - lupus.bmj.com
Background Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease
characterized by pathogenic autoantibodies and tissue damage to multiple organ systems. …

611 Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study

F Liu-Walsh, B van Hartingsveldt, Q Zuraw… - 2022 - lupus.bmj.com
Background Autoantibody-mediated diseases, such as systemic lupus erythematosus (SLE),
are caused by pathogenic antibodies that can damage tissues or organs. Approved …

[CITATION][C] Ex vivo cytokine release from whole blood: a routine method for health effect screening

RPF Schins, B van Hartingsveldt, PJA Borm - Experimental and Toxicologic …, 1996 - Elsevier
Previously, we showed that ex vivo release of TNF by peripheral blood monocytes is a
biological marker for progression of Coal Workers' Pneumoconiosis (CWP), and suggested that …

AB0548 EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DESIGN OF A PHASE 2 STUDY

F Liu-Walsh, BV Hartingsveldt, Q Zuraw, RW Hoffman… - 2023 - ard.bmj.com
… Fang Liu-Walsh Employee of: Janssen Research & Development, LLC and may own
stock or stock options in Johnson & Johnson., Bart van Hartingsveldt Employee of: Janssen …

Cloning, characterization and overexpression of the phytase-encoding gene (phyA) of Aspergillus niger

W Van Hartingsveldt, CMJ van Zeijl, GM Harteveld… - Gene, 1993 - Elsevier
Phytase catalyzes the hydrolysis of phytate (myo-inositol hexakisphosphate) to myo-inositol
and inorganic phosphate. A gene (phyA) of Aspergillus niger NRRL3135 coding for …

Predictive validity of kindergarten assessments on handwriting readiness

MJ van Hartingsveldt, EHC Cup, JCM Hendriks… - Research in …, 2015 - Elsevier
We investigated the predictive value of a new kindergarten assessment of handwriting readiness
on handwriting performance in first grade as evaluated by the Systematic Screening for …